Effect of a PROtein-enriched MEDiterranean diet and EXercise (PROMED-EX) on nutritional status and cognitive performance in older adults at risk of undernutrition and cognitive decline: the PROMED-EX randomized controlled trial.

Am J Clin NutrAug 14, 2026 (epub)
Clinical ResearchGeriatrics

Nicola Ann Ward, Rachel Reid-McCann, Danielle Logan et al.

✦ AI-curated · Sources linked

In 30 seconds

The PROMED-EX randomized controlled trial evaluated the effects of a protein-enriched Mediterranean diet with and without exercise on nutritional status and cognitive performance in 105 older adults at risk of undernutrition. After 6 months, both intervention groups showed significant improvements in nutritional status, with mean MNA score increases of 2.7 for PROMED and 2.9 for PROMED-EX compared to the control group (P < 0.001).

Key findings

  • Nutritional status improved significantly with mean MNA score increases of 2.7 for PROMED and 2.9 for PROMED-EX compared to CON (P < 0.001).
  • Cognitive function improved with NTB z-score differences of 0.3 for PROMED and 0.2 for PROMED-EX compared to CON (P = 0.01 and P = 0.02, respectively).
  • Diet quality scores increased significantly, with mean differences of 4.0 for PROMED and 3.9 for PROMED-EX compared to CON (P < 0.001).

Why it matters

Improving nutritional status in older adults at risk of undernutrition may help mitigate cognitive decline and enhance overall health and quality of life, which is crucial for aging populations.

Source

PubMed · PMID 42680255

Published in Am J Clin Nutr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.